The obtained nanoparticles could protect PTEN-mRNA from degradation in blood circulation following i.v. injection and could efficiently cross the BBB and target GBM via the recognition of the ApoE-peptide and the low-density lipoprotein receptor family expressed on the cell surface. The gene discussed is APOE; the disease is glioblastoma.